Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ruo-Xi Hong"'
Publikováno v:
Chinese Journal of Cancer, Vol 35, Iss 1, Pp 1-7 (2016)
Abstract Background Both hormonal therapy (HT) and maintenance capecitabine monotherapy (MCT) have been shown to extend time to progression (TTP) in patients with metastatic breast cancer (MBC) after failure of taxanes and anthracycline-containing re
Externí odkaz:
https://doaj.org/article/bf5d462f04924360bae25a97f66d5209
Autor:
Zhong-Yu Yuan, Jia-Jia Huang, Shu-Sen Wang, Yong-Yi Zhong, Xin An, Cong Xue, Kui-Kui Jiang, Ruo-Xi Hong, Wen Xia, Ying Guo, Fei Xu, Xin-Mei Liu, Heng Huang, An-Qing Zhang, Le-Hong Zhang, Yuan-Qi Zhang, Zhi-Yong Wu, Ying Lin, Yan-Xia Shi, Jian-Li Zhao, Xi-Wen Bi, Xin Hua
Supplementary Data from Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2a46e9bd87871ba34c28979f9372747
https://doi.org/10.1158/1078-0432.22486484
https://doi.org/10.1158/1078-0432.22486484
Autor:
Zhong-Yu Yuan, Jia-Jia Huang, Shu-Sen Wang, Yong-Yi Zhong, Xin An, Cong Xue, Kui-Kui Jiang, Ruo-Xi Hong, Wen Xia, Ying Guo, Fei Xu, Xin-Mei Liu, Heng Huang, An-Qing Zhang, Le-Hong Zhang, Yuan-Qi Zhang, Zhi-Yong Wu, Ying Lin, Yan-Xia Shi, Jian-Li Zhao, Xi-Wen Bi, Xin Hua
Purpose:There is no research evidence demonstrate which is the better partner strategy, endocrine therapy or chemotherapy, to combine with anti-HER2 therapy as the first-line management of hormone receptor (HR)-positive (HR+) and HER2-positive (HER2+
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::205f3466ab97670a784948795a62ab3a
https://doi.org/10.1158/1078-0432.c.6532331
https://doi.org/10.1158/1078-0432.c.6532331
Autor:
Ying Chen, Wen-Xia Li, Jia-Hua Wu, Geng-Hang Chen, Chun-min Yang, Hai Lu, Xi Wang, Shu-Sen Wang, Heng Huang, Li Cai, Li Zhao, Rou-Jun Peng, Ying Lin, Jun Tang, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, An-Qin Zhang, Fei Xu, Xi-Wen Bi, Jia-Jia Huang, Ji-Bin Li, Dan-Mei Pang, Cong Xue, Yan-Xia Shi, Zhen-Yu He, Huan-Xin Lin, Xin An, Wen Xia, Ye Cao, Ying Guo, Ruo-Xi Hong, Kui-Kui Jiang, Yong-Yi Zhong, Zhong-Yu Yuan, Qian-Jun Chen
Aims: The addition of extended capecitabine after standard neo/adjuvant chemotherapy shows controversial results in triple-negative breast cancer (TNBC) patients between SYSUCC-001 trial and CIBOMA trial. Patients presents different responses to dive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba203628270aa39a470217abf416c999
https://doi.org/10.21203/rs.3.rs-1961186/v1
https://doi.org/10.21203/rs.3.rs-1961186/v1
Publikováno v:
Zhonghua zhong liu za zhi [Chinese journal of oncology]. 35(10)
To investigate the clinical features and prognosis of bone metastases in colorectal cancer patients.The clinical data of 104 cases of colorectal cancer with bone metastasis were collected and retrospectively analyzed.Among all the 104 patients includ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bbfeb2c38e3df34981cbab7ac5cb8094
https://pubmed.ncbi.nlm.nih.gov/24378104
https://pubmed.ncbi.nlm.nih.gov/24378104